0000899243-23-010816.txt : 20230405 0000899243-23-010816.hdr.sgml : 20230405 20230405203012 ACCESSION NUMBER: 0000899243-23-010816 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230403 FILED AS OF DATE: 20230405 DATE AS OF CHANGE: 20230405 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Simon Amy CENTRAL INDEX KEY: 0001963879 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39208 FILM NUMBER: 23804137 MAIL ADDRESS: STREET 1: BEAM THERAPEUTICS, INC. STREET 2: 238 MAIN STREET, 9TH FL. CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Beam Therapeutics Inc. CENTRAL INDEX KEY: 0001745999 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-327-8775 MAIL ADDRESS: STREET 1: 26 LANDSDOWNE STREET CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-03 0 0001745999 Beam Therapeutics Inc. BEAM 0001963879 Simon Amy C/O BEAM THERAPEUTICS INC. 238 MAIN STREET CAMBRIDGE MA 02142 0 1 0 0 Chief Medical Officer 1 Common Stock 2023-04-03 4 S 0 4445 30.31 D 80962 D Common Stock 2023-04-04 4 S 0 10493 29.7664 D 70469 D Common Stock 2023-04-04 4 S 0 1161 29.0926 D 69308 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Includes 278 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.505 to $30.28, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.77 to $29.10, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. By: /s/ Christine Bellon, Attorney-in-fact 2023-04-05